[AI generated, Chat GPT 5.6]
[Links at bottom]
##
Future of Digital Pathology:
Signals from Leica, Mayo, and CAP TODAY
Digital pathology’s next major commercial advance may come when software can assemble a substantially complete pathology report for a physician to review, correct, and sign. That capability could give laboratories a powerful new reason to invest in scanners, image management, AI, and reporting infrastructure: a measurable reduction in the work required to complete a case.
Three recent developments illuminate the path toward that possibility. Leica Biosystems is expanding access to Tempus’s Paige applications within its digital pathology platform. Mayo Clinic Laboratories describes AI assistance across laboratory operations, including draft interpretive reporting. And a CAP TODAY discussion with Digital Pathology Association leaders describes a profession preparing for increasingly comprehensive AI support.
These developments occupy different stages of that trajectory. Together, they suggest that the important question is becoming how effectively digital tools contribute to a completed, clinically useful diagnosis.
Leica and Tempus: Bringing the Components Together
Leica Biosystems’ September 24 announcement adds two Tempus offerings to the Aperio AI Store: Paige PanCancer Detect and the Paige Prostate suite. PanCancer Detect is designed to identify suspicious areas across more than 40 cancer types. The prostate applications address detection, grading and quantification, and perineural invasion.
The announcement emphasizes access through a common workflow. Applications are available within Aperio HALO AP, reducing the need to navigate separate interfaces for different vendors and algorithms. The commercial proposition extends beyond the performance of any individual tool: laboratories need a practical way to bring multiple capabilities into daily work.
The regulatory scope is explicit. The newly announced Paige offerings are for research use only, not diagnostic or clinical use. Aperio HALO AP is also labeled for research use only in the United States. The announcement therefore describes an expansion of research capabilities, rather than a newly available clinical reporting system.
Nevertheless, the direction is significant. Detection, grading, tumor quantification, and assessment of perineural invasion are recognizable components of prostate case interpretation. Bringing them into one environment creates an opportunity to connect their outputs to a larger task.
That larger task is case assembly. A future system would need to associate findings with the correct specimens and cores, reconcile results across slides, identify missing information, and populate a draft report. Leica’s announcement does not claim that capability. It does show increasingly sophisticated analytical components becoming accessible within a shared workflow.
The next competitive question is how much work remains between those outputs and the report the pathologist signs.
Mayo: AI Moves Into Interpretive Drafting
Mayo Clinic Laboratories’ update, “From Intake to Interpretation: How AI Assists Lab Teams Today,” describes a broad operational approach. Applications include extracting information from incoming paperwork, supporting specimen routing, forecasting workload and blood-product demand, assisting with complex analytical signals, and quantifying immunohistochemical staining.
These uses matter because a laboratory’s performance depends on many connected tasks. Faster interpretation cannot fully compensate for delays in specimen intake, missing information, or poorly coordinated capacity.
For the future of reporting, however, the most consequential passage concerns draft interpretations. Mayo describes AI assembling multiple assay results and clinical details into a narrative that a pathologist reviews, edits, and signs. Christopher Garcia, MD, emphasizes bringing information together so that the physician does not begin with a blank page. Authorship and accountability remain with the signing expert.
This moves AI into the production of the laboratory’s professional work product. The benefit potentially includes less information gathering, less repetitive composition, and more consistent incorporation of relevant findings.
The distinction between this capability and comprehensive automated histopathology reporting remains important. Mayo’s account does not demonstrate a general system that reads an entire surgical pathology case and independently generates its complete draft report. Nor does it provide controlled estimates of productivity gains. It does establish that interpretive drafting is part of the institution’s described AI activity.
For the market thesis, that is a meaningful signal. Report assembly is becoming an explicit application category, with physician review built into the workflow.
CAP TODAY: Infrastructure Meets the AI Assistant
CAP TODAY’s September discussion with six Digital Pathology Association leaders places these developments in a broader professional context. Participants describe growing adoption driven by workforce pressures, remote work, access to subspecialists, and precision medicine.
Eric Walk, MD, of PathAI cites a late-2025 survey in which half of laboratories were digital in some capacity. That qualification matters: partial adoption is different from a fully digital diagnostic service. Even so, the discussion portrays a market increasingly concerned with making digital infrastructure productive.
Walk also anticipates AI agents that assist pathologists with primary diagnosis and case workup, drawing an analogy to the preliminary review residents provide in academic departments. Michael Rivers describes the opportunity to combine pathology, sequencing, and clinical information into broader decision support. These are visions of assistance extending across a case.
The panel also identifies substantial unfinished work. Memorial Sloan Kettering’s Orly Ardon emphasizes governance, metadata, quality systems, and accessibility. Performance can vary with patient populations, scanners, and specimen preparation. Bethany Williams highlights the value of data representing diverse practice settings, alongside the continuing challenge of institutional silos.
A second commercial opportunity runs through the discussion: linking diagnostic laboratories with pharmaceutical development, biomarker discovery, and clinical trial enrollment. Digital infrastructure may support both routine diagnostic work and new collaborations. Its value will depend on whether those connections produce useful information at the right point in patient care.
The Convergence: A Report Worth Reviewing
Our white paper at Discoveries in Health Policy from August 2026, proposes that substantially complete, machine-generated draft reports could become the application that sharply accelerates digital pathology adoption. The economic argument is straightforward: reducing the work required to complete cases could strengthen the laboratory’s business case for the entire digital infrastructure.
The three updates make that hypothesis more concrete. Leica illustrates the assembly and distribution of analytical capabilities. Mayo describes interpretive drafting. The CAP TODAY panel anticipates broader case assistance and identifies the infrastructure necessary to support it. None establishes that the commercial tipping point has already arrived.
Shuoshuo Wang’s 2026 article on the pathology report as a “boundary object” helps explain what successful reporting systems will require. A report serves several communities—pathologists, treating physicians, researchers, and others—whose members interpret it using shared knowledge and context. Its concise language can communicate effectively to an expert while leaving relationships insufficiently explicit for computational reuse.
Wang’s argument therefore adds a demanding qualification: extracting individual findings or filling structured fields is insufficient. Systems must preserve which finding belongs to which specimen, where the evidence originated, and what remains uncertain. An unmentioned finding cannot automatically be treated as negative.
Applied to report generation, the implication is clear. A useful draft needs an inspectable connection to the underlying case. Fluent prose alone provides little assurance that those relationships have been preserved.
What Is Needed Now
As analytical tools and drafting capabilities advance, integration becomes more urgent. Outputs need to reach the laboratory information system as usable information, with specimen identity and supporting evidence intact. Pathologists need an efficient way to verify proposed findings, correct them, and recognize unresolved questions.
Evaluation must also move toward the completed case. Relevant measures include total review and correction time, clinically consequential errors, completeness, turnaround time, and performance across different laboratories. A report that appears nearly finished may still require extensive checking; the meaningful endpoint is safe completion with a demonstrable net benefit.
Finally, expert corrections could become a valuable resource for improving future systems. That possibility requires deliberate capture of revisions, appropriate data permissions, and controlled validation of model updates. A signed report is valuable evidence, but it is not automatically an error-free training label.
The strongest market opportunity may belong to systems that make this entire process work reliably: assembling evidence, producing a useful draft, supporting efficient physician review, and delivering a report that others can confidently act upon. Leica, Mayo, and CAP TODAY provide complementary signals that the field is moving toward that objective. The next decisive evidence will concern how much better laboratories can complete the case.
##
.
Leica Biosystems. “Leica Biosystems Brings Tempus Pathology Products to Aperio AI Store, Accelerating AI-Powered Capabilities for Oncology Research.” Press release. September 24, 2026. Official Leica release. Leica Biosystems
Gilligan J. “From Intake to Interpretation: How AI Assists Lab Teams Today.” Mayo Clinic Laboratories, Insights. March 23, 2026. Full article. news.mayocliniclabs.com
CAP TODAY. “DPA Leaders on Digitization, AI, and Deployment.” September 2026. Roundtable moderated by publisher Bob McGonnagle, with Orly Ardon, Nathan Buchbinder, David Lahm, Michael Rivers, Eric Walk, and Bethany Williams. Full interview. captodayonline.com
Bruce Quinn Associates LLC. Digital Pathology Has Been Measuring the Wrong Endpoint? Beyond Srigley’s Six Levels: The Coming Billion-Dollar Hockey Stick. White paper. August 2026; PDF link shared in your LinkedIn post. Blog link.
Wang S. “The Pathology Report as a Boundary Object: From Clinical Communication to Computational Representation.” Precision Pathology. 2026;1:100002. Published online July 25, 2026. doi:10.1016/j.prpath.2026.100002. DOI link.
